Hoechst Pakistan Limited (PSX:HPL)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
3,300.00
-50.63 (-1.51%)
At close: Jul 10, 2025
120.00%
Market Cap 31.67B
Revenue (ttm) 28.03B
Net Income (ttm) 2.07B
Shares Out 9.64M
EPS (ttm) 215.09
PE Ratio 15.27
Forward PE n/a
Dividend 135.00 (4.11%)
Ex-Dividend Date Mar 26, 2025
Volume 1,325
Average Volume 306
Open 3,250.10
Previous Close 3,350.63
Day's Range 3,250.00 - 3,319.99
52-Week Range 1,400.00 - 3,699.99
Beta 0.23
RSI 49.15
Earnings Date Aug 22, 2025

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 837
Stock Exchange Pakistan Stock Exchange
Ticker Symbol HPL
Full Company Profile

Financial Performance

In 2024, Hoechst Pakistan's revenue was 26.75 billion, an increase of 25.17% compared to the previous year's 21.37 billion. Earnings were 1.86 billion, an increase of 414.72%.

Financial Statements

News

There is no news available yet.